[G21-27] Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Last updated 21.10.2021
Project no.:
G21-27
Commission:
Commission awarded on 08.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Application field:
Kidneys and urinary system
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A21-49 | Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-10-21 A G-BA decision was published.